NantOmics

Executive Summary

NantOmics is a private molecular diagnostics company specializing in integrated panomic profiling of cancer tumors, combining whole genome sequencing, RNA sequencing, and quantitative proteomics. Their proprietary analytical platform delivers actionable insights to guide personalized treatment decisions at the point of care. With a focus on comprehensive genomic and proteomic data, the company aims to bridge the gap between multi-omics and clinical practice. Although NantOmics has not disclosed funding or valuation, its niche approach in precision oncology positions it as a potential player in the expanding molecular diagnostics market. The company's ability to secure partnerships or generate clinical validation data will be critical for growth and adoption.

Upcoming Catalysts (preview)

• Q3 2026Partnership with major pharma for companion diagnostics60% success
• Q2 2026Publication of clinical validation study in peer-reviewed journal70% success
• Q4 2026Launch of new liquid biopsy assay for multi-omics profiling50% success